Next Article in Journal
Hedging and Cash Flows in the Presence of Taxes and Expenses in Life and Pension Insurance
Previous Article in Journal
Surrender Risk in the Context of the Quantitative Assessment of Participating Life Insurance Contracts under Solvency II
Previous Article in Special Issue
Risk Aversion, Loss Aversion, and the Demand for Insurance
Article Menu

Export Article

Open AccessArticle
Risks 2018, 6(3), 67; https://doi.org/10.3390/risks6030067

Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

1
ISFA, Laboratoire SAF EA2429, Univ Lyon—Université Claude Bernard Lyon 1, F-69366 Lyon, France
2
Prim’Act, 42 Avenue de la Grande Armée, 75017 Paris, France
These authors are researcher at SAF laboratory (EA n°2429). Frédéric Planchet is also consulting actuary at Prim’Act.
*
Author to whom correspondence should be addressed.
Received: 19 March 2018 / Revised: 14 June 2018 / Accepted: 22 June 2018 / Published: 2 July 2018
(This article belongs to the Special Issue New Perspectives in Actuarial Risk Management)
Full-Text   |   PDF [6327 KB, uploaded 2 July 2018]   |  

Abstract

Pension funds, which manage the financing of a large share of global retirement schemes, need to invest their assets in a diversified manner and over long durations while managing interest rate and longevity risks. In recent years, a new type of investment has emerged, that we call a longevity megafund, which invests in clinical trials for solutions against lifespan-limiting diseases and provides returns positively correlated with longevity. After describing ongoing biomedical developments against ageing-related diseases, we model the needed capital for pension funds to face longevity risk and find that it is far above current practices. After investigating the financial returns of pharmaceutical developments, we estimate the returns of a longevity megafund. Combined, our models indicate that investing in a longevity megafund is an appropriate method to significantly reduce longevity risk and the associated economic capital need. View Full-Text
Keywords: longevity; mortality; longevity risk; pension fund; megafund; biomedical; biology of aging; pharma; model; needed capital longevity; mortality; longevity risk; pension fund; megafund; biomedical; biology of aging; pharma; model; needed capital
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Debonneuil, E.; Eyraud-Loisel, A.; Planchet, F. Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund? Risks 2018, 6, 67.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Risks EISSN 2227-9091 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top